Gout - RxFiles
... 74 µmol/L; fasting glucose was 5.4 mmol/L. Given that weight loss is not likely to provide the same benefits for this patient as would be seen in an obese individual, the final-year medical student working with you today suggests starting treatment with allopurinol. He is uncertain how to do this, a ...
... 74 µmol/L; fasting glucose was 5.4 mmol/L. Given that weight loss is not likely to provide the same benefits for this patient as would be seen in an obese individual, the final-year medical student working with you today suggests starting treatment with allopurinol. He is uncertain how to do this, a ...
Prescribing Information
... NINLARO should be taken once a week on the same day and at approximately the same time for the first three weeks of a four week cycle. NINLARO should be taken at least one hour before or at least two hours after food [see Clinical Pharmacology (12.3)]. The whole capsule should be swallowed with wate ...
... NINLARO should be taken once a week on the same day and at approximately the same time for the first three weeks of a four week cycle. NINLARO should be taken at least one hour before or at least two hours after food [see Clinical Pharmacology (12.3)]. The whole capsule should be swallowed with wate ...
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril
... Background—Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results—We compared the angiot ...
... Background—Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results—We compared the angiot ...
In-Process Revision: LABELING
... Concentrations). Exceptions are oral liquids or solids intended to be constituted to yield oral liquids that, alternatively, can be labeled in terms of each 5-mL portion of the liquid or resulting liquid. Unless otherwise indicated in a monograph or chapter, declarations of strength or quantity shal ...
... Concentrations). Exceptions are oral liquids or solids intended to be constituted to yield oral liquids that, alternatively, can be labeled in terms of each 5-mL portion of the liquid or resulting liquid. Unless otherwise indicated in a monograph or chapter, declarations of strength or quantity shal ...
Non-medical use of olanzapine by people on methadone treatment
... lifetime history of NMU of olanzapine. They did not differ significantly from those without a history of use in terms of gender, age or duration of methadone treatment. Of participants reporting a lifetime history of NMU of olanzapine, two reported currently being prescribed this medication and only ...
... lifetime history of NMU of olanzapine. They did not differ significantly from those without a history of use in terms of gender, age or duration of methadone treatment. Of participants reporting a lifetime history of NMU of olanzapine, two reported currently being prescribed this medication and only ...
Unmet medical need in Allergic Rhinitis and the patient
... • Secondly, the extent to which an individual values a good or service can be described in terms of the levels of these characteristics • The technique involves presenting individuals with choices of scenarios described in terms of attributes and associated levels • Participants are asked to choose ...
... • Secondly, the extent to which an individual values a good or service can be described in terms of the levels of these characteristics • The technique involves presenting individuals with choices of scenarios described in terms of attributes and associated levels • Participants are asked to choose ...
CHRONIC NON-MALIGNANT PAIN (CNMP)
... This table lists various specific pain related conditions that are often included in CNMP. It lists specific drug therapy options that may be considered. Where possible it notes evidence from randomized controlled trials (RCTs) including numbers needed to treat (NNT) for one patient to benefit, and ...
... This table lists various specific pain related conditions that are often included in CNMP. It lists specific drug therapy options that may be considered. Where possible it notes evidence from randomized controlled trials (RCTs) including numbers needed to treat (NNT) for one patient to benefit, and ...
rajiv gandhi university of health sciences
... Amongst the various routes of drug delivery, the oral route is most preferred to the patient and the clinician alike. However, oral administration of drugs has disadvantages such as hepatic first pass metabolism and enzymatic degradation within the gastro intestinal (GIT), that prohibit oral adminis ...
... Amongst the various routes of drug delivery, the oral route is most preferred to the patient and the clinician alike. However, oral administration of drugs has disadvantages such as hepatic first pass metabolism and enzymatic degradation within the gastro intestinal (GIT), that prohibit oral adminis ...
Cellular pH Gradient in Tumor versus Normal Tissue: Potential
... phosphate, because of the relative size of the intracellular compartment and the relative concentration of phosphate in this compartment. pH measured using "P-MRS primarily reflects the aggregate pHi of tissue. ...
... phosphate, because of the relative size of the intracellular compartment and the relative concentration of phosphate in this compartment. pH measured using "P-MRS primarily reflects the aggregate pHi of tissue. ...
evaluation of the effect of lidocain induced local anaesthesia on
... regulation in combating the stress. MATERIALS AND METHODS Patients This study comprised of 30 patients undergoing for wisdom tooth extraction, without having previous history of any other disease was selected as an experimental group. The study has got the approval from Institutional Ethics Committe ...
... regulation in combating the stress. MATERIALS AND METHODS Patients This study comprised of 30 patients undergoing for wisdom tooth extraction, without having previous history of any other disease was selected as an experimental group. The study has got the approval from Institutional Ethics Committe ...
CONCERTA Extended-Release Tablets
... children and adolescents with structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnorma ...
... children and adolescents with structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnorma ...
Abstract
... COX-1 is expressed under basal conditions and is involved in the biosynthesis of PG serving homeostatic functions while COX-2 expression is increased during inflammation and other pathologic situations [2]. The clinical effects of NSAIDs are evaluated in terms of effects on the different COX isoforms. I ...
... COX-1 is expressed under basal conditions and is involved in the biosynthesis of PG serving homeostatic functions while COX-2 expression is increased during inflammation and other pathologic situations [2]. The clinical effects of NSAIDs are evaluated in terms of effects on the different COX isoforms. I ...
clonazepam - Genentech
... different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estima ...
... different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estima ...
MDMA (Ecstasy/Molly)
... salts"). These substances may be extremely dangerous if the user does not know what he or she is taking. They may also be dangerous when combined with MDMA. Users who purposely or unknowingly combine such a mixture with other substances, such as marijuana and alcohol, may be putting themselves at ev ...
... salts"). These substances may be extremely dangerous if the user does not know what he or she is taking. They may also be dangerous when combined with MDMA. Users who purposely or unknowingly combine such a mixture with other substances, such as marijuana and alcohol, may be putting themselves at ev ...
Pharmacological Treatments for PTSD and Comorbid Disorders
... at the moment as a first rank treatment for PTSD; although it is a good treatment for nightmares. Mirtazapine (Remeron) is another effective medication. And finally, Nefazadone, a couple of trials with civilians, and one with Veterans, a very effective drug; of course, the problem with Nefazadone is ...
... at the moment as a first rank treatment for PTSD; although it is a good treatment for nightmares. Mirtazapine (Remeron) is another effective medication. And finally, Nefazadone, a couple of trials with civilians, and one with Veterans, a very effective drug; of course, the problem with Nefazadone is ...
Reflection paper on the data requirements for - EMA
... The documentation required to support regulatory approval of a liposomal formulation developed with reference to an innovator product should be detailed enough to warrant the conclusion of equivalent efficacy and safety compared to the innovator product. In general, the non-clinical studies to be pe ...
... The documentation required to support regulatory approval of a liposomal formulation developed with reference to an innovator product should be detailed enough to warrant the conclusion of equivalent efficacy and safety compared to the innovator product. In general, the non-clinical studies to be pe ...
CALCIJEX - RxAbbVie
... manifested mild hypercalcemia in the first 2 days of life which returned to normal at day 3. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from c ...
... manifested mild hypercalcemia in the first 2 days of life which returned to normal at day 3. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from c ...
to View Essay
... But think about today. No one goes to their doctor asking for penicillin. Why? Penicillin seemed to be the answer to all medical woes. Well, quite simply, it does not work anymore. Penicillin is no longer sufficient to combat modern bacteria. The reason behind that fact boils down to a single idea: ...
... But think about today. No one goes to their doctor asking for penicillin. Why? Penicillin seemed to be the answer to all medical woes. Well, quite simply, it does not work anymore. Penicillin is no longer sufficient to combat modern bacteria. The reason behind that fact boils down to a single idea: ...
Chinese Trial on Isolated Systolic Hypertension in the Elderly
... active study drugs, all labeled A, and the 3 matching placebos, all labeled B. After stratification for sex and cardiovascular complications, eligible patients were alternatingly assigned to type A or type B medication. The first patient of each of the 4 strata always received type A medication. Act ...
... active study drugs, all labeled A, and the 3 matching placebos, all labeled B. After stratification for sex and cardiovascular complications, eligible patients were alternatingly assigned to type A or type B medication. The first patient of each of the 4 strata always received type A medication. Act ...
Lansoprazole/C02-039 A Phase 2, Open-Label Multicenter
... Adverse events were reported by 49% (29/59) of subjects during the IV regimen and 37% (25/68) during the oral regimen. Adverse events that occurred most frequently in subjects during IV dosing included; Injection and Infusion Site Reactions (11/59; 19%), Nausea and Vomiting Symptoms (5/59; 8%), and ...
... Adverse events were reported by 49% (29/59) of subjects during the IV regimen and 37% (25/68) during the oral regimen. Adverse events that occurred most frequently in subjects during IV dosing included; Injection and Infusion Site Reactions (11/59; 19%), Nausea and Vomiting Symptoms (5/59; 8%), and ...
Clinical Practice Guidelines for the Management of Hypertension in
... These guidelines have been written to provide a straightforward approach to managing hypertension in the community. We have intended that this brief curriculum and set of recommendations be useful not only for primary care physicians and medical students, but for all professionals who work as hands- ...
... These guidelines have been written to provide a straightforward approach to managing hypertension in the community. We have intended that this brief curriculum and set of recommendations be useful not only for primary care physicians and medical students, but for all professionals who work as hands- ...
Anti-inflammatory and Analgesic Activity of Methanolic Extract of
... Analgesics are drugs that selectively relieve pain by acting in the CNS or on peripheral pain mechanisms, without significantly altering consciousness. Analgesics relieve pain, without affecting its cause. Analgesics are divided into two groups, opioid analgesic and non-opioid analgesic [3]. The use ...
... Analgesics are drugs that selectively relieve pain by acting in the CNS or on peripheral pain mechanisms, without significantly altering consciousness. Analgesics relieve pain, without affecting its cause. Analgesics are divided into two groups, opioid analgesic and non-opioid analgesic [3]. The use ...
Methamphetamine: A Cinical Primer
... during the withdrawal periods • Intensive therapy is the best hope, but the relapse rate is very high ...
... during the withdrawal periods • Intensive therapy is the best hope, but the relapse rate is very high ...
Exemestane - BC Cancer Agency
... 8. Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology 2000;18(11):2234-44. 9. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to ...
... 8. Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology 2000;18(11):2234-44. 9. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.